Abstract
The role of anthracyclines (ANT) in the treatment of adult acute lymphoblastic leukaemia (ALL) is poorly defined. We reviewed ANT treatment results in adult ALL. Altogether, an early and intensive use of ANT appear to improve both initial response rate and long-term disease-free survival; the new compound idarubicin (IDR) exhibits a consid¬erable antileukaemic activity deserving further evaluation; and the prognosis of CD10+ t(9;22)/BCR-ABL- ALL can be particularly good in relation to an early dose-intensive ANT consolidation program.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ames MM, Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6 (Suppl 1): 70 – 75.
Minderman H, Linssen P, van der Lely N et al. Toxicity of idarubicin and doxorubicin towards normal and leukemic bone marrow progenitors in relation to their proliferative state. Leukemia 1994; 8: 382 – 387.
Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multi-drug resistant leukemia cells. Blood 1992; 79: 3267 – 3273.
Gottlieb AJ, Weinberg W, Ellison RR et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial from Cancer and Leukemia Group B. Blood 1984; 64: 267 – 274.
Ellison RR, Mick R, Cuttner J et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991; 9: 2002 – 2015.
Todeschini G, Meneghini V, Pizzolo G et al. Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994; 8: 376 – 381.
Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica 1995; 80: 282 – 293.
Bassan R, Battista R, D’Emilio A et al. Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia. Eur J Cancer 1991; 27: 441 – 447.
Rohatiner AZS, Bassan R, Battista R et al. High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia. Br J Cancer 1990; 62: 454 – 458.
Bassan R, Battista R, Montaldi A et al. Reinforced HEAVD therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria. Hematol Oncol 1993; 11: 169 – 177.
Bassan R, Battista R, Corneo G et al. Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. Leuk Lymphoma 1993; 11: 105 – 110.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Plenum Press, New York
About this chapter
Cite this chapter
Bassan, D.R. et al. (1996). The Role of Anthracycline S in the Management of Adult Acute Lymphoblastic Leukaemia. In: Abraham, N.G., Asano, S., Brittinger, G., Maestroni, G.J.M., Shadduck, R.K. (eds) Molecular Biology of Hematopoiesis 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0391-6_27
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0391-6_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8031-3
Online ISBN: 978-1-4613-0391-6
eBook Packages: Springer Book Archive